Trial Profile
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 May 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 03 May 2023 Results of phase 1b assessing (n=78; between October 25, 2013, and September 17, 2019) the safety and efficacy of durvalumab plus tremelimumab in adults with Advanced non-small cell lung cancer, published in the Journal of Thoracic Oncology.
- 29 Oct 2019 Status changed from active, no longer recruiting to completed.
- 30 Jul 2019 Planned End Date changed from 24 Apr 2019 to 17 Sep 2019.